Fust Matthew K — SEC insider filings

SEC reporting owner CIK 1397266. 36 insider filings on record with FilingPulse; latest filed 2026-09-01.

Transaction summary — filings shown

Covers all 36 filings on record, filed 2021-06-09 to 2026-09-01. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Crinetics Pharmaceuticals, Inc. (CRNX)Director15—11 legs · 111,700 sh · $4,165,10539
Ultragenyx Pharmaceutical Inc. (RARE)Director8—3 legs · 12,195 sh · $620,44315
Neumora Therapeutics, Inc. (NMRA)Director6—2 legs · 21,788 sh · $370,96227
Atara Biotherapeutics, Inc. (ATRA)Director7—1 leg · 13,354 sh · $260,4039

Insider filings — Fust Matthew K

FiledFormIssuerReported transactionsSource
2026-09-014Crinetics Pharmaceuticals, Inc. (CRNX)Disposition to issuer (D): 22,836 @ $85 · Disposition to issuer (D): 5,925 @ $85 · Disposition to issuer (D): 2,092 (derivative) @ $83.09 · Disposition to issuer (D): 17,500 (derivative) @ $64.68 · Disposition to issuer (D): 12,500 (derivative) @ $40.29 · Disposition to issuer (D): 10,350 (derivative) @ $52.67 · +1 moreEDGAR
2026-06-224Crinetics Pharmaceuticals, Inc. (CRNX)Grant/award (A): 5,925 @ $0 · Grant/award (A): 9,730 (derivative) @ $0EDGAR
2026-06-114Atara Biotherapeutics, Inc. (ATRA)Grant/award (A): 12,000 @ $0EDGAR
2026-05-294Neumora Therapeutics, Inc. (NMRA)Grant/award (A): 80,000 (derivative) @ $0EDGAR
2026-05-184Ultragenyx Pharmaceutical Inc. (RARE)Grant/award (A): 7,751 @ $0 · Grant/award (A): 14,058 (derivative) @ $0EDGAR
2025-09-304Crinetics Pharmaceuticals, Inc. (CRNX)Option exercise (M): 10,000 @ $1.91 · Sale (S): 16,000 @ $44.75 · Option exercise (M): 10,000 (derivative) @ $0EDGAR
2025-06-134Crinetics Pharmaceuticals, Inc. (CRNX)Grant/award (A): 6,900 @ $0 · Grant/award (A): 10,350 (derivative) @ $0EDGAR
2025-06-124Atara Biotherapeutics, Inc. (ATRA)Grant/award (A): 7,828 @ $0EDGAR
2025-05-304Neumora Therapeutics, Inc. (NMRA)Disposition to issuer (D): 85,586 (derivative) · Disposition to issuer (D): 27,802 (derivative) · Disposition to issuer (D): 28,571 (derivative) · Grant/award (A): 85,586 (derivative) · Grant/award (A): 27,802 (derivative) · Grant/award (A): 28,571 (derivative) · +1 moreEDGAR
2025-05-194Ultragenyx Pharmaceutical Inc. (RARE)Grant/award (A): 5,740 @ $0 · Grant/award (A): 10,787 (derivative) @ $0EDGAR
2025-02-184Neumora Therapeutics, Inc. (NMRA)Disposition to issuer (D): 85,586 (derivative) · Disposition to issuer (D): 27,802 (derivative) · Disposition to issuer (D): 28,571 (derivative) · Grant/award (A): 85,586 (derivative) · Grant/award (A): 27,802 (derivative) · Grant/award (A): 28,571 (derivative)EDGAR
2024-10-184Neumora Therapeutics, Inc. (NMRA)Option exercise (M): 3,783 @ $8.32 · Option exercise (M): 1,800 @ $8.79 · Option exercise (M): 2,156 @ $2.52 · Sale (S): 7,739 @ $17.01 · Option exercise (M): 6,205 @ $8.79 · Option exercise (M): 7,844 @ $2.52 · +6 moreEDGAR
2024-06-204Ultragenyx Pharmaceutical Inc. (RARE)Grant/award (A): 5,345 @ $0 · Grant/award (A): 9,900 (derivative) @ $0EDGAR
2024-06-144Neumora Therapeutics, Inc. (NMRA)Grant/award (A): 20,100 @ $0 · Grant/award (A): 28,571 (derivative) @ $0EDGAR
2024-06-114Crinetics Pharmaceuticals, Inc. (CRNX)Grant/award (A): 3,400 @ $0 · Grant/award (A): 12,500 (derivative) @ $0EDGAR
2024-04-024Atara Biotherapeutics, Inc. (ATRA)Grant/award (A): 150,000 @ $0EDGAR
2024-03-224Crinetics Pharmaceuticals, Inc. (CRNX)Option exercise (M): 12,500 @ $23.24 · Sale (S): 12,500 @ $43.57 · Option exercise (M): 12,500 @ $23.23 · Sale (S): 12,500 @ $43.57 · Option exercise (M): 17,500 @ $20.23 · Sale (S): 17,500 @ $43.58 · +6 moreEDGAR
2024-03-114Ultragenyx Pharmaceutical Inc. (RARE)Sale (S): 2,550 @ $50.89 · Sale (S): 2,145 @ $50.85 · Sale (S): 7,500 @ $50.88EDGAR
2023-09-184Neumora Therapeutics, Inc. (NMRA)Grant/award (A): 27,802 (derivative) @ $0EDGAR
2023-06-214Crinetics Pharmaceuticals, Inc. (CRNX)Grant/award (A): 6,000 @ $0 · Grant/award (A): 17,500 (derivative) @ $0EDGAR
2023-06-094Ultragenyx Pharmaceutical Inc. (RARE)Grant/award (A): 3,860 @ $0 · Disposition to issuer (D): 3,300 @ $51.82 · Grant/award (A): 7,110 (derivative) @ $0EDGAR
2023-06-024Atara Biotherapeutics, Inc. (ATRA)Grant/award (A): 57,000 @ $0 · Grant/award (A): 79,500 (derivative) @ $0EDGAR
2022-07-154Crinetics Pharmaceuticals, Inc. (CRNX)Option exercise (M): 5,700 @ $1.45 · Sale (S): 5,700 @ $20.96 · Option exercise (M): 5,700 (derivative) @ $0EDGAR
2022-06-284Ultragenyx Pharmaceutical Inc. (RARE)Grant/award (A): 3,300 @ $0 · Grant/award (A): 6,245 (derivative) @ $0EDGAR
2022-06-274Atara Biotherapeutics, Inc. (ATRA)Grant/award (A): 20,500 @ $0 · Grant/award (A): 31,500 (derivative) @ $0EDGAR
2022-06-214Crinetics Pharmaceuticals, Inc. (CRNX)Grant/award (A): 17,500 (derivative) @ $0EDGAR
2022-03-084Ultragenyx Pharmaceutical Inc. (RARE)Option exercise (M): 7,500 @ $40.37 · Option exercise (M): 7,500 (derivative) @ $0EDGAR
2021-11-054Atara Biotherapeutics, Inc. (ATRA)Sale (S): 13,354 @ $19.50EDGAR
2021-11-034Crinetics Pharmaceuticals, Inc. (CRNX)Option exercise (M): 8,954 @ $1.91 · Sale (S): 8,954 @ $25.50 · Option exercise (M): 8,954 (derivative) @ $0EDGAR
2021-09-094Crinetics Pharmaceuticals, Inc. (CRNX)Option exercise (M): 6,046 @ $1.91 · Sale (S): 6,046 @ $25.50 · Option exercise (M): 6,046 (derivative) @ $0EDGAR
2021-07-274Crinetics Pharmaceuticals, Inc. (CRNX)Option exercise (M): 5,000 @ $1.91 · Sale (S): 5,000 @ $19.59 · Option exercise (M): 5,000 (derivative) @ $0EDGAR
2021-07-204Crinetics Pharmaceuticals, Inc. (CRNX)Option exercise (M): 5,000 @ $1.91 · Sale (S): 5,000 @ $19.50 · Option exercise (M): 5,000 (derivative) @ $0EDGAR
2021-07-134Crinetics Pharmaceuticals, Inc. (CRNX)Option exercise (M): 5,000 @ $1.91 · Sale (S): 5,000 @ $20.71 · Option exercise (M): 5,000 (derivative) @ $0EDGAR
2021-06-284Ultragenyx Pharmaceutical Inc. (RARE)Grant/award (A): 2,145 @ $0 · Grant/award (A): 4,125 (derivative) @ $0EDGAR
2021-06-234Crinetics Pharmaceuticals, Inc. (CRNX)Grant/award (A): 17,500 (derivative) @ $0EDGAR
2021-06-094Atara Biotherapeutics, Inc. (ATRA)Grant/award (A): 11,000 @ $0 · Grant/award (A): 17,500 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2021-06-04 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1397266 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs